{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:21:53Z","timestamp":1767180113990,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1012913","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000}}],"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["212203\/Z\/18\/Z"],"award-info":[{"award-number":["212203\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["212203\/Z\/18\/Z"],"award-info":[{"award-number":["212203\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"\n During drug development, candidate compounds are extensively tested for proarrhythmic risk and in particular risk of Torsade de Pointes (TdP), as indicated by prolongation of the QT interval. Drugs that inhibit the rapid delayed rectifier\n \n \n \n \n \n \n K<\/mml:mtext>\n +<\/mml:mo>\n <\/mml:msup>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n current (\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) can prolong the action potential duration (APD) and thereby the QT interval, and so are routinely rejected. However, simultaneous inhibition of the L-type\n \n \n \n \n \n \n Ca<\/mml:mtext>\n \n 2<\/mml:mn>\n +<\/mml:mo>\n <\/mml:mrow>\n <\/mml:msup>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n current (\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) can mitigate the effect of\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibition, so that including both effects can improve test specificity. Mathematical models of the action potential (AP) can be used to predict the APD prolongation resulting from a given level of\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n and\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibition, but for use in safety-testing their predictive capabilities should first be carefully verified. We present the first systematic comparison between experimental drug-induced APD and predictions by AP models. New experimental data were obtained\n ex vivo<\/jats:italic>\n for APD response to\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n and\/or\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibition by applying 9 compounds at different concentrations to adult human ventricular trabeculae at physiological temperature. Compounds with similar effects on\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n and\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n exhibited less APD prolongation compared to selective\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibitors. We then integrated\n in vitro<\/jats:italic>\n \n \n \n \n \n \n IC<\/mml:mtext>\n \n 50<\/mml:mn>\n <\/mml:mrow>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n patch-clamp data for\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n and\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibition by the tested compounds into simulations with AP models. Models were assessed against the\n ex vivo<\/jats:italic>\n data on their ability to recapitulate drug-induced APD changes observed experimentally. None of the tested AP models reproduced the APD changes observed experimentally across all combinations and degrees of\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n and\/or\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibition: they matched the data either for selective\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibitors or for compounds with comparable effects on\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n and\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n . This work introduces a new benchmarking framework to assess the predictivity of current and future AP models for APD response to\n \n \n \n \n \n \n I<\/mml:mi>\n Kr<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n and\/or\n \n \n \n \n \n \n I<\/mml:mi>\n CaL<\/mml:mi>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n inhibition. This is an essential primary step towards an\n in silico<\/jats:italic>\n framework that integrates\n in vitro<\/jats:italic>\n data for translational clinical cardiac safety.\n <\/jats:p>","DOI":"10.1371\/journal.pcbi.1012913","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T14:22:01Z","timestamp":1751898121000},"page":"e1012913","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of in silico predictions of action potential duration in response to inhibition of IKr and ICaL with new human ex vivo recordings"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2268-5669","authenticated-orcid":true,"given":"Yann-Stanislas H. M.","family":"Barral","sequence":"first","affiliation":[]},{"given":"Liudmila","family":"Polonchuk","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Clerx","sequence":"additional","affiliation":[]},{"given":"David J.","family":"Gavaghan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4569-4312","authenticated-orcid":true,"given":"Gary R.","family":"Mirams","sequence":"additional","affiliation":[]},{"given":"Ken","family":"Wang","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"2","key":"pcbi.1012913.ref001","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","article-title":"A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel","volume":"81","author":"MC Sanguinetti","year":"1995","journal-title":"Cell"},{"issue":"1","key":"pcbi.1012913.ref002","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"WS Redfern","year":"2003","journal-title":"Cardiovasc Res"},{"issue":"7","key":"pcbi.1012913.ref003","first-page":"473","article-title":"Drug-induced QT prolongation and torsades de pointes","volume":"42","author":"M Li","year":"2017","journal-title":"P T"},{"key":"pcbi.1012913.ref004","unstructured":"ICH G. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals. 2005. https:\/\/www.ich.org\/page\/safety-guidelines"},{"key":"pcbi.1012913.ref005","unstructured":"ICH G. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14. 2006. https:\/\/wwwichorg\/page\/efficacy-guidelines"},{"issue":"1","key":"pcbi.1012913.ref006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk","volume":"91","author":"GR Mirams","year":"2011","journal-title":"Cardiovasc Res"},{"issue":"2","key":"pcbi.1012913.ref007","article-title":"Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-\u00e0-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology","volume":"10","author":"Z Li","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"pcbi.1012913.ref008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - update on progress","volume":"81","author":"T Colatsky","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"5","key":"pcbi.1012913.ref009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"L Johannesen","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"pcbi.1012913.ref010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.vascn.2014.07.002","article-title":"Prediction of thorough QT study results using action potential simulations based on ion channel screens","volume":"70","author":"GR Mirams","year":"2014","journal-title":"J Pharmacol Toxicol Methods"},{"key":"pcbi.1012913.ref011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2016.09.011","article-title":"Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes","volume":"100","author":"SA Mann","year":"2016","journal-title":"J Mol Cell Cardiol"},{"issue":"5","key":"pcbi.1012913.ref012","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","volume":"7","author":"T O\u2019Hara","year":"2011","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"pcbi.1012913.ref013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.yjmcc.2009.09.019","article-title":"A novel computational model of the human ventricular action potential and Ca transient","volume":"48","author":"E Grandi","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"pcbi.1012913.ref014","volume-title":"ToR-ORd-dynCl: an update of the ToR-ORd model of human ventricular cardiomyocyte with dynamic intracellular chloride","author":"J Tomek","year":"2020"},{"key":"pcbi.1012913.ref015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3389\/fphys.2017.01059","article-title":"Global optimization of ventricular myocyte model to multi-variable objective improves predictions of drug-induced torsades de pointes","volume":"8","author":"T Krogh-Madsen","year":"2017","journal-title":"Front Physiol"},{"key":"pcbi.1012913.ref016","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fphys.2020.00314","article-title":"Simulation of the effects of extracellular calcium changes leads to a novel computational model of human ventricular action potential with a revised calcium handling","volume":"11","author":"C Bartolucci","year":"2020","journal-title":"Front Physiol"},{"issue":"1","key":"pcbi.1012913.ref017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1085\/jgp.96.1.195","article-title":"Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents","volume":"96","author":"MC Sanguinetti","year":"1990","journal-title":"J Gen Physiol"},{"key":"pcbi.1012913.ref018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejphar.2007.02.049","article-title":"Adenoviral-mediated expression of dihydropyridine-insensitive L-type calcium channels in cardiac ventricular myocytes and fibroblasts","volume":"565","author":"KB Walsh","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"pcbi.1012913.ref019","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/cpt.1647","article-title":"General principles for the validation of proarrhythmia risk prediction models: an extension of the CiPA in silico strategy","volume":"107","author":"Z Li","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"pcbi.1012913.ref020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Z Li","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"pcbi.1012913.ref021","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1540-8159.1998.tb00148.x","article-title":"Taking the \u201cidio\u201d out of \u201cidiosyncratic\u201d: predicting torsades de pointes","volume":"21","author":"DM Roden","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"pcbi.1012913.ref022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bpj.2015.12.012","article-title":"The cardiac electrophysiology web lab","volume":"110","author":"J Cooper","year":"2016","journal-title":"Biophys J"},{"issue":"2","key":"pcbi.1012913.ref023","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: a pharma industry perspective","volume":"109","author":"HM Vargas","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"pcbi.1012913.ref024","first-page":"53","volume-title":"Pharmacological and regulatory aspects of QT prolongation. Methods and principles in medicinal chemistry","author":"F De Ponti","year":"2008"},{"key":"pcbi.1012913.ref025","article-title":"Effects of chlorpromazine on Na+-K+-ATPase pumping and solute transport in rat hepatocytes","volume":"253","author":"RW Van Dyke","year":"1987","journal-title":"Am J Physiol"},{"issue":"9","key":"pcbi.1012913.ref026","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1440-1681.2002.03731.x","article-title":"Mode-dependent inhibition by quinidine of Na+-Ca2+ exchanger current from guinea-pig isolated ventricular myocytes","volume":"29","author":"YH Zhang","year":"2002","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"pcbi.1012913.ref027","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: superior to the HERG model in predicting Torsade de Pointes","volume":"3","author":"J Kramer","year":"2013","journal-title":"Sci Rep"},{"key":"pcbi.1012913.ref028","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"WJ Crumb","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"3","key":"pcbi.1012913.ref029","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpj.2020.11.666","article-title":"Drug effects on human Na(+)\/Ca(2+)exchanger and implications for drug development","volume":"120","author":"M Barthmes","year":"2021","journal-title":"Biophys J"},{"issue":"2","key":"pcbi.1012913.ref030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vascn.2010.02.007","article-title":"Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37\u2009degrees C: Cisapride versus dofetilide","volume":"61","author":"JT Milnes","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"7","key":"pcbi.1012913.ref031","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.16250","article-title":"The impact of uncertainty in hERG binding mechanism on in silico predictions of drug-induced proarrhythmic risk","volume":"181","author":"CL Lei","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"2","key":"pcbi.1012913.ref032","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/jpp.JPP_158_17","article-title":"Investigation of hERG1b influence on hERG channel pharmacology at physiological temperature","volume":"9","author":"A Harchi","year":"2018","journal-title":"J Pharmacol Pharmacother"},{"issue":"23","key":"pcbi.1012913.ref033","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1304382110","article-title":"Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology","volume":"110","author":"OJ Britton","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1012913.ref034","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vascn.2016.05.016","article-title":"Human ex-vivo action potential model for pro-arrhythmia risk assessment","volume":"81","author":"G Page","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"9","key":"pcbi.1012913.ref035","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00556.2014","article-title":"Cardiac tissue slices: preparation, handling, and successful optical mapping","volume":"308","author":"K Wang","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"pcbi.1012913.ref036","doi-asserted-by":"crossref","DOI":"10.22489\/CinC.2022.356","article-title":"Normalisation of action potential data recorded with sharp electrodes maximises its utility for model development.","volume-title":"2022 Computing in Cardiology Conference (CINC)","author":"YS Barral","year":"2022"},{"key":"pcbi.1012913.ref037","first-page":"4","article-title":"The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves","volume":"40","author":"A Hill","year":"1910","journal-title":"J Physiol"},{"issue":"1","key":"pcbi.1012913.ref038","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41598-020-62344-w","article-title":"Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells","volume":"10","author":"J Kramer","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"pcbi.1012913.ref039","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/acs.jcim.9b01085","article-title":"When does the IC50 accurately assess the blocking potency of a drug?","volume":"60","author":"J Gomis-Tena","year":"2020","journal-title":"J Chem Inf Model"},{"issue":"4","key":"pcbi.1012913.ref040","article-title":"A model for human ventricular tissue","volume":"286","author":"KHWJ ten Tusscher","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"pcbi.1012913.ref041","article-title":"Alternans and spiral breakup in a human ventricular tissue model","volume":"291","author":"KHWJ ten Tusscher","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"pcbi.1012913.ref042","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fphys.2017.00616","article-title":"Optimization of an in silico cardiac cell model for proarrhythmia risk assessment","volume":"8","author":"S Dutta","year":"2017","journal-title":"Front Physiol"},{"issue":"5","key":"pcbi.1012913.ref043","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/bioinformatics\/btq723","article-title":"The physiome model repository 2","volume":"27","author":"T Yu","year":"2011","journal-title":"Bioinformatics"},{"key":"pcbi.1012913.ref044","doi-asserted-by":"crossref","first-page":"879035","DOI":"10.3389\/fphys.2022.879035","article-title":"A parameter representing missing charge should be considered when calibrating action potential models","volume":"13","author":"Y-SHM Barral","year":"2022","journal-title":"Front Physiol"},{"key":"pcbi.1012913.ref045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-030-73317-9_137-1","article-title":"Computational cardiac safety testing","volume-title":"Drug discovery and evaluation: safety and pharmacokinetic assays","author":"G Mirams","year":"2023"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1012913","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T18:03:46Z","timestamp":1752257026000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012913"}},"subtitle":[],"editor":[{"given":"Alain","family":"Nogaret","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1012913","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}